Immunotherapy at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
17 organizations at ASCO 2027 present work in immunotherapy: 16 drug developers and 1 advocacy group, society, cancer center, publisher or agency. 17 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–17 of 17 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
Akeso Zhongshan City, China | |
Chinese antibody drugmaker with bispecific immunotherapies, including the PD-1/VEGF antibody ivonescimab for lung cancer. | Booth Exhibiting at Booth 37147 |
ALX Oncology South San Francisco, CA | |
Clinical-stage immuno-oncology biotech developing evorpacept, a CD47 blocker, with positive data in HER2-positive gastric cancer. | Booth Exhibiting at Booth IH09 |
BeOne Medicines Basel, Switzerland | |
Global oncology company, formerly BeiGene, marketing zanubrutinib for blood cancers and the PD-1 antibody tislelizumab. | Booth Exhibiting at Booth 24021, 24033 |
BioNTech Mainz, Germany | |
Immunotherapy company developing mRNA cancer vaccines, a PD-L1/VEGF bispecific antibody, antibody-drug conjugates and CAR-T cell therapies. | Booth Exhibiting at Booth 24103 |
Bristol Myers Squibb Lawrence Township, NJ | |
Global drugmaker with immuno-oncology medicines such as nivolumab, plus myeloma, lymphoma and other blood cancer drugs and CAR-T cell therapies. | Booth Exhibiting at Booth 15093 |
Coherus Oncology Redwood City, CA | |
Immuno-oncology company marketing the PD-1 antibody toripalimab (Loqtorzi) for nasopharyngeal cancer and developing further immunotherapies. | Booth Exhibiting at Booth 10095 |
GSK London, UK | |
Global drugmaker with cancer medicines for gynecologic and blood cancers, including the PD-1 antibody dostarlimab and myeloma treatments. | Booth Exhibiting at Booth 19059 |
Henlius Shanghai, China | |
Shanghai biopharma making biosimilars and novel antibodies, including the PD-1 antibody serplulimab and a trastuzumab biosimilar. | Booth Exhibiting at Booth IH03 |
ImmunityBio Culver City, CA | |
Immunotherapy company marketing Anktiva, an IL-15 agonist for BCG-unresponsive bladder cancer, and developing NK cell therapies and vaccines. | Booth Exhibiting at Booth 23148 |
Immunocore Abingdon, UK | |
Commercial-stage biotech behind Kimmtrak (tebentafusp), the first approved T cell receptor therapy, for uveal melanoma; developing more bispecific TCR drugs. | Booth Exhibiting at Booth 25157 |
Merck Rahway, NJ | |
Global drugmaker behind the PD-1 antibody pembrolizumab (Keytruda), with cancer trials in over 30 tumor types and a growing ADC pipeline. | Booth Exhibiting at Booth 14013 |
Moderna Cambridge, MA | |
mRNA medicines company developing individualized cancer vaccines, including intismeran autogene with Merck for melanoma, alongside infectious disease vaccines. | Booth Exhibiting at Booth 24149 |
Regeneron Sleepy Hollow, NY | |
Biotechnology drugmaker whose cancer medicines include cemiplimab (Libtayo) for skin and lung cancers and bispecific antibodies for myeloma and lymphoma. | Booth Exhibiting at Booth 11111 |
Replimune Woburn, MA | |
Biotech developing oncolytic immunotherapies built on an engineered herpes simplex virus, led by RP1 for advanced melanoma. | Booth Exhibiting at Booth 31165 |
Society for Immunotherapy of Cancer Milwaukee, WI | |
Professional society advancing cancer immunotherapy science and practice; publishes the Journal for ImmunoTherapy of Cancer. | Booth Exhibiting at Booth 13040 |
Summit Therapeutics Miami, FL | |
Biotech developing ivonescimab, a PD-1/VEGF bispecific antibody, in Phase 3 trials for non-small cell lung and colorectal cancers. | Booth Exhibiting at Booth 35144 |
Syncromune Fort Lauderdale, FL | |
Clinical-stage biotech developing SYNC-T, an in-tumor immunotherapy pairing partial cryolysis with intratumoral drug infusion for metastatic solid tumors. | Booth Exhibiting at Booth 10058 |
Instantly find 20 buyers in immunotherapy
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction